TY - JOUR AU - Loyd, Michael AU - Rublee, Dale AU - Jacobs, Philip PY - 2007 DA - 2007/07/04 TI - An economic model of long-term use of celecoxib in patients with osteoarthritis JO - BMC Gastroenterology SP - 25 VL - 7 IS - 1 AB - Previous evaluations of the cost-effectiveness of the cyclooxygenase-2 selective inhibitor celecoxib (Celebrex, Pfizer Inc, USA) have produced conflicting results. The recent controversy over the cardiovascular (CV) risks of rofecoxib and other coxibs has renewed interest in the economic profile of celecoxib, the only coxib now available in the United States. The objective of our study was to evaluate the long-term cost-effectiveness of celecoxib compared with nonselective nonsteroidal anti-inflammatory drugs (nsNSAIDs) in a population of 60-year-old osteoarthritis (OA) patients with average risks of upper gastrointestinal (UGI) complications who require chronic daily NSAID therapy. SN - 1471-230X UR - https://doi.org/10.1186/1471-230X-7-25 DO - 10.1186/1471-230X-7-25 ID - Loyd2007 ER -